Streetbeat News

Regulatory

SHPH

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) announced that TCG GreenChem has completed the initial manufacturing of the active pharmaceutical ingredient (API) of Ropidoxuridine for use in the company's upcoming Phase II clinical trial in brain cancer patients undergoing radiation therapy. The company's request for a Type B pre-IND meeting with the FDA for guidance on the proposed Phase II clinical trial has been approved, with responses expected by September 18, 2023. The company aims to commence its Phase II clinical study in the fourth quarter of 2023.

Portfolio Pulse from Happy Mohamed

August 04, 2023 | 1:24 pm

USO

Saudi Arabia has decided to extend its voluntary oil cut of 1 million barrels per day (BPD) for another month, including September, according to the state news agency.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:22 pm

SPY

The number of initial jobless claims was reported to be 227K, which is in line with the estimates.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:22 pm

CMPS

PSIL

Portugal has decriminalized synthetic drugs, potentially impacting the global market for such substances. Clinical trials show promising results for psilocybin therapy in treating anorexia, with COMPASS Pathways' synthetic psilocybin COMP360 treatment showing potential. MindBio Therapeutics Corp. is recruiting participants for a clinical trial using LSD microdosing for cancer patients with emotional distress. California's TREAT initiative proposes a $5 billion state agency to fund and promote psychedelics research. The AdvisorShares Psychedelics ETF (PSIL) showed a slight uptake in the past week.

Portfolio Pulse from Lara Goldstein

August 04, 2023 | 1:20 pm

FEMY

Femasys Inc. (NASDAQ:FEMY) has initiated enrollment in a multi-center pivotal trial for its permanent birth control candidate, FemBloc. The trial, named FINALE, aims to investigate the safety and efficacy of FemBloc, addressing the high unmet need for women seeking permanent birth control for whom elective surgery remains the only option.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:19 pm

SPY

The nonfarm productivity for Q2 has been reported at 3.7%, significantly higher than the expected 2.0% and a substantial improvement from the previous -2.1%.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:18 pm

GOOG

GOOGL

Elon Musk's company, X (formerly Twitter), is being sued by French news agency Agence France-Presse (AFP) for not compensating it for news articles appearing on the platform. The lawsuit is based on a 2019 French legislation that extends copyright protection to content produced by news publishers. AFP has previously sued Alphabet Inc.'s Google on similar grounds.

Portfolio Pulse from Rounak Jain

August 04, 2023 | 1:18 pm

AGFAF

CCHWF

CRLBF

NLVVF

PLNHF

SNDL

XXII

Shawn Collins, the head of Massachusetts cannabis regulator, is set to step down by the end of the year, causing concerns within the commission. Maryland Governor Wes Moore has enlisted experts to assess the health impact of cannabis as sales surge in the state. Shareholders of Planet 13 Holdings, SNDL Inc., and Agra Ventures have elected new board members. Cresco Labs and Columbia Care have terminated their merger agreement, with Columbia Care announcing senior leadership changes. 22nd Century Group has appointed John Miller as interim CEO, and New Leaf Ventures has named Dean Medwid as CEO following the resignation of Michael Stier.

Portfolio Pulse from Jelena Martinovic

August 04, 2023 | 1:18 pm

BWAY

BrainsWay Ltd. (BWAY) announced three new research publications on its Deep Transcranial Magnetic Stimulation (Deep TMS™) technology. Two publications focus on the safety profile of TMS, while the third discusses the use of TMS for treating smoking addiction and other substance use disorders. BrainsWay's Deep TMS™ is the only FDA-cleared TMS solution for any addiction.

Portfolio Pulse from Happy Mohamed

August 04, 2023 | 1:17 pm

MMV

MultiMetaVerse Holdings Limited has received a notification from Nasdaq regarding a deficiency in its minimum market value. The company now has 180 days to regain compliance.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:17 pm